Astellas Pharma: Xtandi Plus Leuprolide Cut Metastasis Risk 58%

Astellas Pharma and Pfizer said Xtandi plus leuprolide significantly reduced the risk of metastasis or death by 58% versus placebo plus leuprolide.

• The phase 3 study was carried out in men with non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence, the companies said in a statement
• NOTE: Astellas Says Xtandi, Leuprolide P3 Study Met Primary Endpoint

To view the source of this information, click here

To contact the reporter on this story:
Susanne Barton in Houston at swalker33@bloomberg.net

To contact the editor responsible for this story:
Chakradhar Adusumilli at cadusumilli@bloomberg.net

© 2023 Bloomberg L.P. All rights reserved. Used with permission. ...